| Name | HS-243 |
| Description | HS-243 is an inhibitor of IRAK-4 and IRAK-1 with IC50s of 20 and 24 nM. HS-243 shows anti-inflammatory and anticancer activity. |
| In vitro | HS-243 shows minimal TAK1 (transforming growth factor β-activated kinase 1) inhibition activity, with a IC50 of 0.5 μM. HS-243 (0-10 μM) inhibits cell survival by 21% for AN3-CA pancreatic cancer cells, and 13% for SKOV-3 ovarian cancer cells. HS-243 (10 μM) potently reduces the pro-inflammatory response of RA cells and macrophages and significantly reduces the secretion of 15 cytokines, including IL-8, CD14, GRO-α, MIP-1a, MIP-3a, uPAR, Osteopontin, MMP-9, MCP-1, I-TAC, TIM-3, IP-10, GDF-15, and RANTES[1]. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 10 mg/mL (30.83 mM), Sonication is recommended.
|
| Keywords | tumor necrosis factor | TNF | THP-1 | TAK1 | rheumatoid arthritis | RA-FLSs | IRAK-4 | IRAK-1 | IRAK | Interleukin-1 receptor associated kinase | interleukin | Inhibitor | inhibit | immunology | IL-1R associated kinase | HS-243 | HS243 | HS 243 | H460 | Cyclin dependent kinase | CLK4 | CDK | autoimmune disease | anti-inflammatory | AN3-CA |
| Inhibitors Related | Ribociclib | Amantadine | 2-Chloropyrazine | Kojic acid | Abemaciclib | ANTHRAQUINONE-2-CARBOXYLIC ACID | 2,4,6-Trihydroxybenzoic acid | Phosphocreatine disodium | Palbociclib | Sodium Oxamate | Sodium new houttuyfonate | DHBP |
| Related Compound Libraries | Osteogenesis Compound Library | Anti-Pancreatic Cancer Compound Library | Bioactive Compound Library | Pain-Related Compound Library | Kinase Inhibitor Library | Inhibitor Library | Anti-Aging Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library | MAPK Inhibitor Library |